Cellivery, Consecutive Patent Registrations for Platform Core Technologies

[Asia Economy Reporter Hyunseok Yoo] Cellivery announced on the 7th that its proprietary drug delivery technology, the Therapeutic Substance Delivery Technology (TSDT), has been granted a patent in Canada after more than three years of examination, recognizing its novelty and inventive step.

A company official stated, "The TSDT platform technology, for which the patent registration has been completed, and the cell membrane-penetrating peptide aMTD applied to it, are our company's core drug development platform technologies," adding, "Patents have been filed in 33 major countries worldwide, including the 27 countries of the European Union."

The official explained, "Among these, the patent registration in the United States, which has the most stringent examination and is difficult to register, was successful, and patents have currently been registered in five countries including Australia, Korea, Japan, and Canada (1.8%)." He further noted, "Examinations are ongoing in the European Union and China, so it is expected to cover most of the global pharmaceutical market."

Cellivery currently holds a total of 15 intellectual property rights, including five patents for the core TSDT platform technology, one patent for a pancreatic cancer anticancer drug (United States), one for a liver cancer anticancer drug (United States), three for Parkinson's disease treatment drugs (Japan, Europe, Australia), one for a bone formation-promoting biobetter (United States), one for a severe obesity treatment drug (United States), one for genome editing technology (Europe), and two for pluripotent stem cell production technology (United States, Europe).

In particular, with the success of the Canadian patent registration, the entire North American region, including the United States, is now covered. The company explained that this will greatly strengthen licensing-out (L/O) negotiations with global pharmaceutical companies based in North America?which accounts for the largest portion of the pharmaceutical market (42%)?and with global pharmaceutical companies seeking licensing rights in the North American region.

This Canadian patent recognizes the scope of rights not only for 136 sequences of the cell membrane-penetrating peptide aMTD, which enables the conversion of various pharmacological substances into new drug candidates, but also for the manufacturing method that produces the aMTD peptide. Since rights have been acquired for the manufacturing method as well, it is impossible for competitors to imitate the delivery peptide itself, making it one of the strongest rights at the highest level for a platform technology patent, according to the company.

CEO Daewoong Cho emphasized, "We have devoted great effort to securing intellectual property (IP), which incurs enormous costs for application and registration, as well as substantial annual maintenance fees, and we are now reaping the results of those efforts." He added, "We have a firm belief in the core TSDT platform technology and have high expectations for the licensing-out (L/O) deal amounts that will be generated relative to the costs invested."

This content was produced with the assistance of AI translation services.